By Kevin E. Noonan –
In a nonprecedential opinion, the Federal Circuit affirmed a decision by the Patent Trial and Appeal Board that the claim challenged in an ex parte reexamination was invalid for anticipation in In re Magnolia Medical
Patent Law Weblog, published by Patent Docs, focuses on issues related to U.S. patent law, including subject matter eligibility under 35 U.S.C. § 101, patentability standards, and recent developments in patent examination policies. The blog covers topics such as the impact of court decisions on patent eligibility, challenges in patenting computer-implemented inventions, and administrative guidance from the USPTO. It also discusses patent disputes, regulatory actions affecting pharmaceutical patents, and evolving interpretations of inventorship, especially in the context of AI-assisted inventions. The blog provides analysis of legal standards, procedural updates, and policy shifts influencing patent prosecution and enforcement.
By Kevin E. Noonan –
In a nonprecedential opinion, the Federal Circuit affirmed a decision by the Patent Trial and Appeal Board that the claim challenged in an ex parte reexamination was invalid for anticipation in In re Magnolia Medical…
By Michael Borella –
More than a decade after Alice Corp. v. CLS Bank Int’l, the two-step framework for patent eligibility under 35 U.S.C. § 101 remains as contentious as ever. Courts, commentators, and the U.S. Patent and Trademark…
By Kevin E. Noonan –
The Federal Circuit affirmed a District Court determination that method claims reciting administration of a modification of an established antibiotic by adding magnesium to the composition were infringed and not invalid in Melinta Therapeutics, LLC…
By Michael Borella –
By Donald Zuhn –
The U.S. Patent and Trademark Office has published a final rule in the Federal Register (an unpublished version of the notice, which will be published on June 24, can be found here), in which the…
By Kevin E. Noonan –
In a nonprecedential decision, the Federal Circuit recently affirmed a district court’s finding that innovator drugmaker Otsuka Pharmaceutical failed to show generic competitor Lupin infringed (or would infringe, if it marketed an FDA-approved generic version…
The Supreme Court issued an Order this morning denying certiorari in Newman v. Moore. The Court’s Order states that:
The motion for leave to file a brief in opposition under seal with redacted copies for the public record is granted. …
By Kevin E. Noonan –
At the beginning of June, the New Civil Liberties Alliance (representing Judge Paulene Newman) filed the Judge’s Reply Brief to the Federal Circuit Judicial Council’s Opposition to her Petition for Certiorari*. The brief specifically identifies…
By Kevin E. Noonan –
The Judicial Council of the Federal Circuit, represented by the U.S. Solicitor General, recently filed its Respondents’ Brief in Opposition to Judge Pauline Newman’s Petition for Certiorari. While the brief followed its expected path of…
By Kevin E. Noonan –
In a decision that, in retrospect, is not surprising (in view of the haste with which the Court took up the case after granting certiorari; see “Solicitor General Proves Persuasive; Supreme Court Grants Hikma’s…